Literature DB >> 17531777

Major ABO blood group mismatch increases the risk for graft failure after unrelated donor hematopoietic stem cell transplantation.

Mats Remberger1, Emma Watz, Olle Ringdén, Jonas Mattsson, Agneta Shanwell, Agneta Wikman.   

Abstract

Two hundred twenty-four patients with leukemia transplanted with an unrelated donor between 1991 and 2003 at the Karolinska University Hospital were analyzed according to association between graft failure and ABO, RhD, MNSs, and Kidd blood group antigen compatibility. Median age was 29 years (range: 0-55). Conditioning consisted of total-body irradiation or busulfan-based myeloablative conditioning. A bone marrow graft was given to 152 patients, and 72 patients received peripheral blood stem cells. Most patients received graft-versus-host disease prophylaxis with cyclosporine and MTX. Graft failure (GF) was seen in 6 (2.7%) patients. In the multivariate analysis major ABO mismatch (odds ratio [OR] 14.9, 95% confidence interval [CI] 2.01-110, P = .008) and HLA-allele mismatch (6.42, 1.19-34.8, P = .03) was significantly associated to GF. In patients with and without major ABO mismatch the incidence of GF was 7.5% and 0.6% (P = .02), respectively. Using an ABO major mismatched graft increases the risk for GF after unrelated donor hematopoietic stem cell transplantation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17531777     DOI: 10.1016/j.bbmt.2007.01.084

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  14 in total

1.  Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning.

Authors:  Stephanie B Tsai; Hongtao Liu; Tsiporah Shore; Yun Fan; Michael Bishop; Melissa M Cushing; Usama Gergis; Lucy Godley; Justin Kline; Richard A Larson; Guadalupe Martinez; Sebastian Mayer; Olatoyosi Odenike; Wendy Stock; Amittha Wickrema; Koen van Besien; Andrew S Artz
Journal:  Biol Blood Marrow Transplant       Date:  2016-02-19       Impact factor: 5.742

2.  Impact of Graft-Recipient ABO Compatibility on Outcomes after Umbilical Cord Blood Transplant for Nonmalignant Disease.

Authors:  Matthew R Kudek; Ryan Shanley; Nicole D Zantek; David H McKenna; Angela R Smith; Weston P Miller
Journal:  Biol Blood Marrow Transplant       Date:  2016-08-02       Impact factor: 5.742

3.  Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis.

Authors:  H Alchalby; D-R Yunus; T Zabelina; F Ayuk; N Kröger
Journal:  Bone Marrow Transplant       Date:  2016-04-18       Impact factor: 5.483

4.  Consequences of ABO incompatibility in multiple myeloma patients undergoing peripheral blood stem cell transplantation after reduced intensity conditioning.

Authors:  Dario Marenchino; Laura Maddalena; Riccardo Balbo; Ilaria Avonto; Giuseppe Menardi; Maristella Prucca; Laura Perotti; Nicola Mordini; Gianmichele Peano
Journal:  Blood Transfus       Date:  2010-05-19       Impact factor: 3.443

Review 5.  Graft failure after allogeneic hematopoietic cell transplantation.

Authors:  Jonas Mattsson; Olle Ringdén; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2008-01       Impact factor: 5.742

Review 6.  A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation.

Authors:  James L Gajewski; Viviana V Johnson; S Gerald Sandler; Antoine Sayegh; Thomas R Klumpp
Journal:  Blood       Date:  2008-06-26       Impact factor: 22.113

7.  Menstrual blood cells display stem cell-like phenotypic markers and exert neuroprotection following transplantation in experimental stroke.

Authors:  Cesar V Borlongan; Yuji Kaneko; Mina Maki; Seong-Jin Yu; Mohammed Ali; Julie G Allickson; Cyndy D Sanberg; Nicole Kuzmin-Nichols; Paul R Sanberg
Journal:  Stem Cells Dev       Date:  2010-04       Impact factor: 3.272

8.  Palifermin mediates immunoregulatory effects in addition to its cytoprotective effects in mice with acute graft-versus-host disease.

Authors:  Cynthia A Ellison; Bryce M Makar; Jacqie M M Wiseman; Ionela Gheorghiu; Masaru Taniguchi; John G Gartner
Journal:  J Clin Immunol       Date:  2008-07-01       Impact factor: 8.317

Review 9.  ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Nina Worel
Journal:  Transfus Med Hemother       Date:  2015-10-29       Impact factor: 3.747

10.  The impact of donor type and ABO incompatibility on transfusion requirements after nonmyeloablative haematopoietic cell transplantation.

Authors:  Zejing Wang; Mohamed L Sorror; Wendy Leisenring; Gary Schoch; David G Maloney; Brenda M Sandmaier; Rainer Storb
Journal:  Br J Haematol       Date:  2010-01-11       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.